This Article Full Text Full Text (PDF) RPHR Note Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Salehi, M. Articles by D'Alessio, D. A. Search for Related Content PubMed PubMed Citation Articles by Salehi, M. Articles by D'Alessio, D. A.

Targeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins

Department of Medicine, Division of Endocrinology, University of Cincinnati, Cincinnati, Ohio 45267-0547

Correspondence: Address all correspondence and requests for reprints to: David D'Alessio, Department of Medicine, Division of Endocrinology, ML 0547, University of Cincinnati, Vontz Center for Molecular Studies, 3125 Eden Avenue, Cincinnati, Ohio 45267-0547. E-mail: dalessd{at}ucmail.uc.edu

Progressive insulin secretory defects, due to either functional abnormalities of the pancreatic β-cells or a reduction in β-cell mass, are the cornerstone of type 2 diabetes. Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on β-cell physiology as well as by expanding or at least maintaining β-cell mass, which may delay the progression of the disease. Long-term studies in humans are needed to elaborate on these effects.

This article has been cited by other articles:

				D. A. Cunha, L. Ladriere, F. Ortis, M. Igoillo-Esteve, E. N. Gurzov, R. Lupi, P. Marchetti, D. L. Eizirik, and M. Cnop Glucagon-Like Peptide-1 Agonists Protect Pancreatic {beta}-Cells From Lipotoxic Endoplasmic Reticulum Stress Through Upregulation of BiP and JunB Diabetes, December 1, 2009; 58(12): 2851 - 2862. [Abstract] [Full Text] [PDF]

				S. B. Widenmaier, Z. Ao, S.-J. Kim, G. Warnock, and C. H. S. McIntosh Suppression of p38 MAPK and JNK via Akt-mediated Inhibition of Apoptosis Signal-regulating Kinase 1 Constitutes a Core Component of the {beta}-Cell Pro-survival Effects of Glucose-dependent Insulinotropic Polypeptide J. Biol. Chem., October 30, 2009; 284(44): 30372 - 30382. [Abstract] [Full Text] [PDF]

				O. P. McGuinness, J. E. Ayala, M. R. Laughlin, and D. H. Wasserman NIH experiment in centralized mouse phenotyping: the Vanderbilt experience and recommendations for evaluating glucose homeostasis in the mouse Am J Physiol Endocrinol Metab, October 1, 2009; 297(4): E849 - E855. [Abstract] [Full Text] [PDF]

				S. B. Widenmaier, A. V. Sampaio, T. M. Underhill, and C. H. S. McIntosh Noncanonical Activation of Akt/Protein Kinase B in {beta}-Cells by the Incretin Hormone Glucose-dependent Insulinotropic Polypeptide J. Biol. Chem., April 17, 2009; 284(16): 10764 - 10773. [Abstract] [Full Text] [PDF]

				D. A. D'Alessio, A. M. Denney, L. M. Hermiller, R. L. Prigeon, J. M. Martin, W. G. Tharp, M. L. Saylan, Y. He, B. E. Dunning, J. E. Foley, et al. Treatment with the Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves Fasting Islet-Cell Function in Subjects with Type 2 Diabetes J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 81 - 88. [Abstract] [Full Text] [PDF]